BioCentury provides business intelligence services focused on the biopharma industry, helping to explore company profiles, find investment opportunities, and track competitive threats.

BioCentury

BioCentury Inc. | 8,573 followers on LinkedIn. BioCentury gives biopharma executives, investors and institutions the power to make business-critical decisions through independent, deep-dive analysis; high-quality data; and industry-leading business intelligence, and global events.

When you subscribe to BioCentury, our team of Ph.D.s, analysts and industry experts become an extension of your team, helping you answer critical questions, decipher strategic trends, objectively evaluate product and business strategies, and assess competitive, financial, and policy risks. We also help you to build your network by connecting you the who’s who in the industry.

Ron Rabinowitz

Marketing Technology & Business Operations Specialist

Adam Gordon

Orlando Abello

Editor in Chief, BioCentury Inc.

Simone Fishburn

BioCentury Inc.

Companies, advocates, researchers push back against New York Times claims that they should have disclosed genetic info to Alzheimer's trial participants

Are you attending London Life Sciences Week or the Jefferies London Healthcare Conference? If so, please join BioCentury Inc. and BioIndustry Association (BIA) on Nov. 19 (5pm-9pm) for our 2nd CEO and Investor Dialogue and networking reception. ✅ Register: https://lnkd.in/diW7CaNb Speakers include: ► E. Eric Tokat of Centerview Partners ► Dr. Jeremy M. Levin of Ovid Therapeutics ► Laura A. Lane of Eli Lilly and Company ► Michael Margolis of Oppenheimer & Co. Inc. ► Evan Matlin of MTS Health Partners ► Chris Sheldon, PhD of GSK ► Erica Whittaker of UCB Ventures ► Steve Bates OBE FMedSci of BIA ► and my BioCentury colleagues Simone Fishburn and Stephen Hansen Seats are limited. If you are a BIA member or BioCentury subscriber, send me a DM to receive a member-only discount. Hope to see you in London! #biotech #biopharma #venturecapital #LLSW2024

Joshua Berlin

Probe intensifies spotlight on AstraZeneca in China: Global pharmas and local biotechs weigh fallout of investigation into AZ China head

Myths and misperceptions. What are biotechs, pharmas and academics getting wrong about each other?

What separates successful investors from those who fall behind? The ability to identify opportunities before they become obvious. At our upcoming virtual Drug Development Disco, Joel Sandler, Ph.D. , Nicholas Mitchell, Ph.D. and Matt Krebs dive deep into how you can refine your discovery process, spot the unseen, and turn insights into investments.

.@EliLillyandCo discontinued PD-1 agonist peresolimab last week, but was the target the problem? @AnaptysBio and Santa Ana Bio are making the case for optimized agonistic antibody designs that could more effectively repurpose the cancer target for inflammatory diseases.

Thank you to everyone that joined us for the 11th #BioCenturyChinaSummit in Shanghai! While in-person sessions have ended, you can still register for a digital pass to access live recordings of the sessions and schedule virtual partnering meetings with delegates (Nov. 5-6). Learn more: https://lnkd.in/gTiC3vY2

The BayHelix Woman Leader of the Year award goes to Dr. Michelle Yu Xia - Founder, Chairwoman, President & CEO of Akeso Biopharma ! As the founder of one China’s fastest-rising biotechs, Dr. Xia had a banner year in 2024, with Akeso’s bispecific ivonescimab beating Merck’s Keytruda in a China Phase 3 study in NSCLC. On behalf of the BioCentury-BayHelix China Healthcare Summit, congratulations! View all winners: https://lnkd.in/gjrr6ukJ The BayHelix Group #BioCenturyChinaSummit #biotech #lifesciences #investor #biopharma #venturecapital #drugdevelopment #businessdevelopment

The BayHelix Company of the Year award goes to Legend Biotech ! Founded in 2014, Legend had a landmark year in 2024, propelled by a second-line approval for multiple myeloma for its CAR T product Carvykti. The product, partnered with J&J, continues to widen the sales gap over Bristol Myers Squibb's competing CAR T, Abecma. On behalf of the BioCentury-BayHelix China Healthcare Summit, congratulations! View all winners: https://lnkd.in/gjrr6ukJ The BayHelix Group #BioCenturyChinaSummit #biotech #lifesciences #investor #biopharma #venturecapital #drugdevelopment #businessdevelopment

The BayHelix Commercial Achievement of the Year award goes to XtalPi Inc. ! The company’s AI and robotics-enabled drug discovery solutions business saw rapid growth in 2024, helping to drive investor interest as it became the first company to list under HKEX’s 18C rules, raising roughly HK$1B. On behalf of the BioCentury-BayHelix China Healthcare Summit, congratulations! View all winners: https://lnkd.in/gjrr6ukJ The BayHelix Group #BioCenturyChinaSummit #biotech #lifesciences #investor #biopharma #venturecapital #drugdevelopment #businessdevelopment

Metric
Company Name	BioCentury
Symbol
MSH ID	COM:BIOCENTURY:PROFILES
Market	PRIVATE
Sector	Commercial & Professional Services
Industry	Healthcare & Health Services
Country	US
Stage
Employee Count
Website	profiles.biocentury.com
LinkedIn	biocentury-publications
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

BIOC

COM:BIOCENTURY:PROFILES

BioCentury

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue